# Index


Abdominal aortic aneurysm exclusion, 177–9
ACE inhibition and diabetes, 165, 167–8
Acute coronary occlusion, 91–109
Acute myocardial infarction (AMI)
  diabetes, 166–7
  factors linked to arrhythmias, 193–6
  management of, 89–112
    with acute coronary occlusion, 91–109
  natural history, 89–90
  opening the occluded artery, 98–109
  pathology, 90–1
Acute chest pain, 32–3
Adenoviral vector gene therapy, 220–1
Adjunctive therapy, 102–3
Afro-Caribbean and CHD risk, 16
Age-related CHD risk (elderly), 15–16
Alcohol, 126–7
AMI *see* Acute myocardial infarction
Amiodarone, 145–6
**Anagnostopoulos C, Hencin MY, Underwood SR**: Non-invasive investigations, 29–44
Angina
  due to underlying CAD, laser treatment, 249–59
  revascularisation with diabetes, 166
  stable, 17–27
Angina, chronic refractory,
  neuromodulation for 269–78
  TENS treatment, 269–71
Angina, unstable, 69–87
  classification of, 70
  clinical presentation, 70–1
  and congestive heart failure treatment, 183–4
  in-hospital management, first 48 h, 71–9
  later in-hospital management, 79–83
  preliminary investigations, 71–3
Angiogenesis, protein and gene delivery: **Azrin M**, 211–25
Angioplasty *versus* Minimally Invasive Surgery Trial – AMIST trial, 264
Angioplasty
  balloon (*see* PCI), 47–9
  primary, for AMI, 104–9
Angiotensin converting enzyme (ACE) inhibitors, 114, 116–19, 140–2
    aspirin and, 149–50
  receptor antagonists, 140–2
Anti-arrhythmic agents, 97–8
Anti-ischaemic therapy, 118,
Antioxidant vitamins, 97–8, 126
Antiplatelet therapy and diabetes, 164
Antithrombotic therapy, 73, 76, 147–50
  aspirin, 73
  beta-blockers, 76–8
  calcium channel blockers, 77–8
  glycoprotein IIb/IIIa receptor antagonists, 74
  heparin (fractionated and unfractionated), 75–6
  intra-aortic balloon pump, 78
  nitrates, 77
  potassium channel openers, 78
  thienopyridines, 74–5
Aorto-iliac disease, 173–9
Arrhythmias, 20
  IHD presenting as, 193–210
Arteriogenesis, definition of, 212
Aspirin, 73–4
  and ACE inhibitors, 149–50
  and diabetes, 167
Asymptomatic individuals with CHD – risk stratification in the prevention of : **Wood D**, 3–16
Atherogenesis, accelerated in diabetes, 159–61
Atherosclerotic disease
  linked to infection, 62–3
  risk and prevention, 3–16
Atrial tachyarrhythmias, 204–5
**Azrin M**: Angiogenesis, protein and gene delivery, 211–25

Beta Blocker Heart Attack Trial, (BHAT), 117
Beta-blockers, 76–7, 78, 142–5
Bilateral internal thoracic artery (ITA), 51
Blood pressure
  lowering and diabetes, 162
  management and CHD risk assessment, 11–13
Braunwald class A, angina exacerbated by intercurrent illness, 71
CABG *see* Coronary artery bypass grafting




© The British Council 2001

CAD *see* Coronary artery disease
Calcium
  antagonists, 146
  channel blockers, 77–8
**Camm AJ** *see* **Ghuran AV**
Cardiac
  care, post-hospital, 115–19
  catheterisation, 80–1
  failure, 19–20, 116–18
  rehabilitation, 82–3, 113–33
  transplantation, 25
Cardiovascular risk and diabetes, 161
Carotid artery (subclavian) disease, 186–9
**Chaubey S, Davies SW, Moat N:** Invasive investigations and revascularisation, 45–53
CHD *see* Coronary heart disease
Chest pain
  acute, 32–3
  chronic, 32
  clinical diagnosis of, 20–24
  differential diagnosis of, 17–20
**Chester M** *see* **Moore R**
Cholesterol management and CHD risk assessment, 13–14
Chronic refractory angina, neuromodulation for, 269–78
**Clark A** *see* **Cleland JGF**
**Clarke SC, Schofield PM:** Laser revascularisation, 249–59
**Cleland JGF, John J, Dhawan J, Clark A:** What is the optimal medical management of ischaemic heart failure? 135–56
Clinical presentation and diagnosis of coronary artery disease: stable angina: **Davies SW**, 17–27
Complete heart block (CHB), 205–7
Compliance and psychosocial issues in rehabilitation, 119–20, 127–9
Conduction disturbances, 205–8
Congestive heart failure and treatment of unstable angina, 183–4
Coronary angiography, 80
Coronary artery bypass grafting (CABG) 49–50, 52
  through limited access with the use of extracorporeal circulation (port access CABG), 265–6
Coronary artery bypass surgery, 82
  *see* Percutaneous coronary intervention
Coronary artery calcification
  detection of, 65
  score, 23, 46
Coronary artery disease (CAD)
  diagnosis, 32–3
  prognosis, 33–4
  and stable angina, 17–27
Coronary heart disease (CHD)
  asymptomatic individuals – risk stratification in prevention, 3–16
  risk and diabetes mellitus, 14–15
    protection against, 161–5
Coronary occlusion, acute, 91–5
Coronary revascularisation, 81–2, 151–2
Coronary risk factors, rehabilitation lifestyle changes, 120–7
C-reactive protein (CRP), inflammation marker, 63–4, 71

**Davies SW, Gershlick AH:** Preface, 1–2
**Davies SW** *see* **Chaubey S**
**Davies SW:** Clinical presentation and diagnosis of coronary artery disease: stable angina, 17–27
**Dhawan J** *see* **Cleland JGF**
Diabetes
  and CHD risk, 14–15, 25
  **Timmis AD**, 159–72
Diagnosis (clinical) of chest pain, 20–25
  diabetes mellitus, 25
  elderly, 25
  after MI, 25
  after cardiac transplantation, 25
Diagnostic steps in patients with heart failure and IHD, 138–9
Dietary modification, 123–7
Direct myocardial revascularisation (DMR), 253–9
Drug delivery
  for angiogenesis, 214–5
  (local) and stent development, 227–48
Dyslipidaemia and diabetes, 160–1
Dyspnoea, 19

Echocardiography (ECG)
  for imaging the effects of CAD, 38–42, 71
  long-axis function during stress, 41–2
  myocardial viability and hibernation, 41
  resting, 38–9
  stress, 39–41, 46, 80
  transoesophageal, 38
  transthoracic, 38
Electron beam computed tomography (EBCT), 65

Endothelial cell dysfunction, 55–6
Endothelium derived relaxing factor (EDRF), 56
Ethnic minorities and CHD risk, 16
Exercise
  ECG, 35, 80
  in rehabilitation, 120–2, 125
Extracranial carotid artery disease, 186–9

Fibroblast growth factor (FGF), 214
  protein therapy
    for MI, 221–2
    for peripheral vascular disease, 222–3
**Fox KAA** *see* **Newby DE**

Gender difference in CHD risk, 15
Gene delivery – angiogenesis, 211–25
  viral and non-viral, 215–16, 219–21
**Gershlick AH, Davies SW**: Preface, 1–2
**Gershlick AH**: The acute management of myocardial infarction, 89–112
**Ghuran AV, Camm AJ**: Ischaemic heart disease presenting as arrhythmias, 193–210
Glycaemic control and diabetes, 163–4
Glycoprotein IIb/IIIa (GPIIb/IIIa) receptor antagonists, 74, 93, 103–4
GPIIb/IIIa *see* glycoprotein IIb/IIIa

HDL *see* High density lipoproteins
Heart failure and diabetes, 168
**Henein MY** *see* **Anagnostopoulos C**
Heparin (anticoagulant), 75–6
High density lipoproteins (HDL)
  and CHD risk assessment, 13–14
Hirudin, 76
Hydrallazine and nitrates, 145
Hypercholesterolaemia
  diabetes and, 14
  familial, 14
  Indo-Asian descent, 14, 16
Hyperglycaemia and diabetes, 160
Hyperinsulinaemia and insulin resistance, 160
Hyperlipidaemia, 14, 15
Hypertension
  and proteinuria co-existence, as a marker for CHD, 15
  renovascular, treatment of, 183
IHD *see* Ischaemic heart disease

Iliac artery intervention, 174–6
Imaging, 64–5
Implantable cardioverter defibrillators (ICD), 198, 202–3
Infection, atherosclerosis linked to, 62–3
Inflammatory mechanisms: **Farzaneh-Far A, Rudd J, Weissberg PL**, 55–68
Intercellular adhesion molecules 1 (ICAM 1), 58–9, 64, 66
Invasive (minimally) therapy and robotics, 261–8
Invasive investigations and revascularisation: **Chaubey S, Davies SW, Moat N**, 45–53
Ischaemic heart disease presenting as arrhythmias: **Ghuran AV & Camm AJ**, 193–210
Ischaemic heart disease (IHD), later management of documented, secondary prevention and rehabilitation, 113–33
Ischaemic heart failure, optimal medical management of, 135–56

**John J** *see* **Cleland JGF**

Laser revascularisation: **Clarke SC, Schofield PM**, 249–59
Later management of documented ischaemic heart disease: secondary prevention and rehabilitation: **McLeod AA**, 113–33
LDL *see* Low density lipoproteins
Left anterior descending (LAD) artery, 51
  coronary artery occulsion, 211–13, 221, 262
Left internal thoracic artery (LITA), 51
Lifestyle modification of coronary risk factors in rehabilitation, 120–7
Lipid
  lowering therapy, 150
  modification and diabetes, 162–3
Lipids and CHD risk assessment, 13–14
Low density lipoprotein (LDL), 57, 58–9
  and CHD risk assessment, 13–14

Magnesium, 97
Magnetic resonance imaging (MRI), 23, 65
  MR angiography, 23
Matrix metalloproteinases (MMPs), 61, 66
**McLeod AA**: Later management of documented ischaemic heart disease: secondary prevention and rehabilitation, 113–33
Methoxy-isobutyl-isonitrile, 31

MI *see* Myocardial infarction/ischaemia
MIBI *see* Tc-99m-2-methoxy-isobutyl-isonitrile, 31, 37
Minimally invasive
direct coronary artery bypass (MIDCAB), 52, 262–8
therapy and robotics: **Spyt TJ, De Souza AC**, 261–8
**Moat N** *see* **Chaubey S**
Mobitz heart block, 205
Monocyte chemo-attractant protein-1 (MCP-1), 58–9
**Moore R, Chester M**: Neuromodulation for chronic refractory angina, 269–78
MPS *see* Myocardial perfusion scintigraphy
Myocardial hibernation, 29, 36–38
Myocardial infarction/ischaemia (MI), 116
management of acute, 9, 19, 25, 89–112
Myocardial perfusion scintigraphy (MPS) for imaging the effects of CAD, 29–44
basic principles, 29–32
clinical applications, 32–38
Myocardial revascularisation, 36
Myocardial viability and hibernation, 36–38, 41

Natural history of AMI, 89–90
Neuromodulation for chronic refractory angina: **Moore R, Chester M**, 269–78
Neuromodulation, general mechanisms of action, 273–6
**Newby DE, Fox KAA**: Unstable angina: the first 48 hours and later in-hospital management, 69–87
Nitrates, 77, 96–7, 145
Nitric oxide (NO), 56–7
Nitric oxide synthase (NOS), 56–7
Non-invasive coronary assessment, 22
Non-invasive investigations: **Anagnostopoulos C, Henein MY, Underwood SR**, 29–44
Non-surgical treatment of patients with peripheral vascular disease: **White CJ**, 173–92
Non-sustained ventricular tachycardia (NSVT), 197, 198

Off pump CABG (OPCAB), 264–5
Optimal medical management of ischaemic heart failure, 135–56

Oxidative stress, 56–7
Pathology of AMI: impact on early strategies, 90–1
Percutaneous coronary intervention (PCI), 47
PCI *see* Percutaneous coronary intervention
Percutaneous myocardial laser revascularisation (PMR), 50
for angina with CAD, 252–59
Peripheral vascular disease, non-surgical treatment of patients with, 173–92
PET *see* Positron emission tomography
Phytosterols, 125–6
Plaque stability, 60–2
Plasma lipid modification, 118–19
Port access CABG, 265–6
Positron emission tomography (PET) scanning, 23, 37, 65
Potassium channel openers, 78
Preface: **Gershlick AH, Davies SW**, 1–2
Prevention and rehabilitation: later management of documented ischaemic heart disease, 113–33
Prevention of CHD, WHO Expert Committee on, 3–4
Prevention, secondary, 82–3
Procoagulation factors and diabetes, 161
Prognosis, adverse, for patients with unstable angina, 79–80
Prognostic assessment of CAD, 46–7
Psychosocial and compliance issues in rehabilitation, 119–20, 127–9

Radio-isotope myocardial perfusion scanning, 23
Radiopharmaceuticals, 31–2
Tc-99m-2-methoxy-isobutyl-isonitrile (MIBI), 31, 37
thallium-201 imaging, 37
Refractory angina, chronic, neuromodulation for, 269–78
**Regar E, Sianos G, Serruys PW**: Stent development and local drug delivery, 227–48
Rehabilitation and prevention: later management of documented IHD, 113–33
Renal artery stenosis, 179–84
Renal failure, chronic, and CHD, 15
Revascularisation
angina with diabetes, 166
coronary, 81–2, 151–2
invasive investigations, 45–53
surgical, indications and trials, 49–52

using lasers, 249–59
Right internal thoracic artery (RITA), 51
Risk assessment
before non-cardiac surgery, 35–6
in unstable angina, 79–80
Risk concept and calculation of CHD, 4–9
Risk management, asymptomatic healthy individuals, 9–11
Risk stratification
in the prevention of, CHD, 3–16
of CAD, 46–7
Robotics, minimally invasive therapy and, 261–8

**Schofield PM** *see* **Clarke SC**
Screening for CHD with diabetes, 165–6
**Serruys PW** *see* **Regar E**
Serum amyloid A (SAA), 63
**Sianos G** *see* **Regar E**
Silent ischaemia, 24
Sinus
bradycardia, 203
tachycardia, 204
Smoking cessation, 123, 147
and diabetes, 163
SPECT *see* Single photon emission computed tomography, 29, 38
Spinal cord stimulation (SCS) for intractable angina, 271–2, 276
Spironolactone, 145
**Spyt TJ, De Souza AC**: Minimally invasive therapy and robotics, 261–8
Stable angina: clinical presentation and diagnosis of coronary artery disease, 17–27
Statins as plaque stabilizers, 65–6
Stent development and local drug delivery: **Regar E, Sianos G, Serruys PW**, 227–48
Stenting (*see* PCI), 47–9
Stress echocardiography, 23, 39–41, 46
Stress induction, forms of, 30–1
Subclavian artery disease/stenosis, 184–5
Sudden cardiac death (SCD) and ICDs, 202–3
Sudden death, 20
and diabetes, 167–8
Supraventricular arrhythmias, 203–5
Surgical conduit for CABG, 50–1
Sustained ventricular tachycardia (SVT), 199–202

Targets for thrapy in patients with heart failure, 136–8
Tetrofosmin, 37
The acute management of myocardial infarction: **Gershlick AH**, 89–112
Thienopyridines, 74
Thrombolysis, 91–2, 94–5, 98–102, 108–9
**Timmis AD**: Diabetes, 159–72
Trancutaneous electrical nerve stimulation (TENS) for improving microcirculatory blood flow in unstable angina, 269–71, 276
Transmyocardial laser revascularisation (TMR), 50
for angina with CAD , 250–59
Treatments for patients with heart failure and IHD, 139–52
Tumour necrosis factor alpha (TNF-α), 61, 63

**Underwood SR** *see* **Anagnostopoulos C**
Unstable angina: the first 48 hours and later in-hospital management: **Newby DE, Fox KAA**, 69–87

Vascular cell adhesion molecules-1 (VCAM-1), 58, 64, 66
Vascular endothelial growth factor (VEGF), 213–4
adenoviral vector gene therapy, 220–1
plasmid DNA therapy, 219–20
protein therapy, 217–19, 221–3
Vascular smooth muscle cells (VSMC) and atherosclerotic plaque, 59–62, 66–7
Ventricular
arrhythmias, 196–202
fibrillation (VF), 202
premature complexes (VPCs), 196–7
tachycardia (VT), 197–202
Very low density lipoproteins (VLDL) and CHD risk assessment, 13–14
VLDL *see* Very low density lipoproteins

Warfarin, 150
Weight reduction, 127
What is the optimal medical management of ischaemic heart failure? **Cleland JGF, John J, Dhawan J, Clark A**, 135–56
**White CJ**: Non-surgical treatment of patients with peripheral vascular disease, 173–92
**Wood D**: Asymptomatic individuals – risk stratification in the prevention of coronary heart disease, 3–16
World Health Organization Expert Committee on Prevention of CHD, 3